Lundbeck reported robust Q4 and FY 16 results, largely in line with our estimates. NB all sales numbers in LC, unless specified otherwise. Q4 16 sales were up 11% to DKK4.2bn (12% in DKK), mainly driven by five key products – Rexulti (+360%), Northera (+62%), Brintellix/Trintellix (+57%), Abilify Maintena (+47%) and Onfi (+21%). Core EBIT reached DKK1bn from DKK73m in Q4 15 (the margin increased c.22ppt to 24%), primarily benefiting from the positive product mix and the ongoing restruct
20 Feb 2017
Solid FY 17 guidance; confirms shelving of Idalopirdine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid FY 17 guidance; confirms shelving of Idalopirdine
Lundbeck reported robust Q4 and FY 16 results, largely in line with our estimates. NB all sales numbers in LC, unless specified otherwise. Q4 16 sales were up 11% to DKK4.2bn (12% in DKK), mainly driven by five key products – Rexulti (+360%), Northera (+62%), Brintellix/Trintellix (+57%), Abilify Maintena (+47%) and Onfi (+21%). Core EBIT reached DKK1bn from DKK73m in Q4 15 (the margin increased c.22ppt to 24%), primarily benefiting from the positive product mix and the ongoing restruct